Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im] and ruthenium uptake by tumor cells

Anti-Cancer Drugs

Volumn 7, Issue 6, 1996, Pages 697-702

  Bergamo, Alberta ^a   Cocchietto, Moreno ^a   Capozzi, Ilaria ^a   Mestroni, Giovanni ^b   Alessio, Enzo ^b   Sava, Gianni ^b  

^a Institutes of Biological Research   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Antimetastatic; Residual metastasis; Ruthenium; Ruthenium determination

Indexed keywords

ANTIMETASTATIC AGENT; RUTHENIUM DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; DIMETHYL SULFOXIDE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM, RESIDUAL; ORGANOMETALLIC COMPOUNDS; RUTHENIUM; SURVIVAL ANALYSIS;

EID: 0029965599     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199608000-00011     Document Type: Article

References (17)

1. 4(DMSO)Im] on solid mouse tumours. Anti-Cancer Drugs 1992; 3: 25-31.
2. 4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metastasis 1992; 10: 273-80.
3. 4(DMSO)Im] in the mouse. Clin Exp Metastasis 1994; 12: 93-100.
4. Mestroni G, Alessio E, Sava G. Pacor S, Coluccia M, Boccarelli A. Water soluble ruthenium(III)-dimethyl sulfoxide complexes: chemical behaviour and pharmacological properties. Metal Based Drugs 1993; 1: 41-63.
5. Sava G Giraldi T, Lassiani L, Nisi C. Mechanism of the antimetastatic action of dimethyltriazenes Cancer Treat Rep 1979; 63: 93-8.
6. Giraldi T, Sava G. Selective antimetastatic drugs (review). Anticancer Res 1980; 1: 163-74.
7. Giraldi T, Sava G. Malignancy and tumour proteinases: effects of proteinase inhibitors. In: Turk V, Vitale L, eds. Proteinases and their inhibitors. Structure, function and applied aspects. Oxford: Pergamon Press 1981: 45-56.
8. Giraldi T, Sava G, Cuman R, Nisi C, Lassiani L. Selectivity of the antimetastatic and cytotoxic effects of 1-p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt, (±)-1,2-di(dioxopiperazin-1-yl)propane and cyclophosphamide in mice bearing Lewis lung carcinoma. Cancer Res 1981; 41: 2524-8.
9. Honn KV. Inhibition of tumour cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis 1983; 1: 103-14.
10. Sava G, Perissin L, Zorzet S, Piccini P, Giraldi T. Antimetastatic action of the prostacyclin analog Iloprost in the mouse. Clin Exp Metastasis 1989; 7: 671-8.
11. 4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex. Drug Invest 1994; 8: 150-61.
12. Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G, Alessio E. Effects of ruthenium complexes on experimental tumours: irrelevance of cytotoxicity for metastasis inhibition. Chem-Biol Interact 1995; 95: 109-26.
13. 4(DMSO)Im] in the mouse. Clin Exp Metastasis 1994; 12: 93-100.
14. 4(DMSO)Im].2DMSO. Drugs of the Future 1993; 18: 894-900.
15. 3. Inorg Chim Acta 1993; 203: 205-17.
16. Poliak-Blazi M, Boranic M, Marzan B, Radacic M. A transplantable aplastic mammary carcinoma of CBA mice. Vet Arh 1981; 51: 99-107.
17. Sava G, Capozzi I, Bergamo A, et al. Down regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an antimetastatic ruthenium complex. Int J Cancer 1996; in press.